This Toast Analyst Sees Surge In GLP-1 Drugs & More Spoiling Long Term Growth Prospects
Mizuho Securities analyst Dan Dolev downgraded Toast Inc (NYSE: TOST), a digital technology platform built for restaurants, to Neutral from Buy and lowered the